The test analyzes digital biopsy images to help predict treatment response and long-term outcomes for patients with localized prostate cancer.
CorePlus, a digital clinical laboratory in Puerto Rico, has integrated the ArteraAI Prostate Test into its diagnostic workflow. This marks the first time the artificial intelligence test has been brought into routine clinical use in the region to provide treatment insights for localized prostate cancer.
The ArteraAI Prostate Test uses a multimodal artificial intelligence platform to analyze digital pathology images of prostate cancer biopsies. Unlike many laboratory-developed tests, the process analyzes images of existing histopathology slides and does not consume additional tissue. Following a validation process, CorePlus transmits biopsy slide images to Artera and typically receives results within 24 hours.
Determining the appropriate treatment for prostate cancer is a challenge for clinicians because the disease varies in aggressiveness, which can lead to over-treatment or under-treatment. According to the press release, the ArteraAI Prostate Test is the only test included in clinical guidelines from the National Comprehensive Cancer Network that can both predict therapy benefit and forecast long-term outcomes in localized prostate cancer.
“Through persistence and precision, our teams have delivered AI-enabled insights to our largely underserved patient population, faster and more conveniently than even most leading academic centers,” says Mariano de Socarraz, CEO of CorePlus, in a release. “CorePlus continues its important mission of transforming patient care through precision pathology, turning years of research into real-life impact for patients.”
The collaboration also includes research into the effectiveness of the tool within specific populations. Juan C Santa Rosario, chief medical officer of CorePlus, will present joint research titled “Validation of a multimodal AI biomarker in a Puerto Rican cohort with localized prostate cancer” at the Digital Pathology Association’s PathVisions conference on Oct 17, 2026.
“At Artera, our mission in making precision oncology accessible means proving it works across every community, and Dr Santa Rosario’s research reinforces this,” says Andre Esteva, CEO and co-founder of Artera, in a release. “By combining innovative digital pathology with multimodal data analysis, we provide clinicians with the tools they need to deliver truly personalized care.”
ID 67032078 © Bobby17 | Dreamstime.com
